Clinical trial for curative treatment of incurable diseases by using herbal drug.

Phase 2 clinical trial for assessment of safety and efficacy of a multi component botanical therapeutic (SKB108) for chronic inflammatory diseases

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/10/010214

Enrollment

800

Registered

2017-10-26

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients having confirmed diagnosis of chronic inflammatory disease(s) at least from one year

Interventions

Intervention1: SKB108: Oral administration of 400 mg capsule/25 kg body weight/day of SKB108 for effective duration of time. Control Intervention1: No comparator agent: Not applicable

Eligibility

Inclusion criteria

Inclusion criteria: Patients having confirmed diagnosis of chronic inflammatory disease(s).

Exclusion criteria

Exclusion criteria: Healthy human patients suffering from a disease which is not a chronic inflammatory disease

Design outcomes

Primary

Measure	Time frame
Complete freedom from chronic inflammatory disease(s)Timepoint: 6 months	—

Secondary

Measure	Time frame
Complete freedom from chronic inflammatory disease(s)Timepoint: 5 years	—

Countries

India

Contacts

Public ContactAshok Kumar

SK Biotherapeutics Pvt. Ltd. (Previously SK Biolabs)

ashok846@gmail.com8126688922

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026